Last reviewed · How we verify
Rizatriptan co-administered with Acetaminophen
Rizatriptan selectively binds to serotonin 5-HT1B/1D receptors to constrict cranial blood vessels and inhibit neuropeptide release, while acetaminophen provides additional analgesic and antipyretic effects through COX inhibition.
Rizatriptan selectively binds to serotonin 5-HT1B/1D receptors to constrict cranial blood vessels and inhibit neuropeptide release, while acetaminophen provides additional analgesic and antipyretic effects through COX inhibition. Used for Acute migraine with or without aura.
At a glance
| Generic name | Rizatriptan co-administered with Acetaminophen |
|---|---|
| Sponsor | Diamond Headache Clinic |
| Drug class | Triptan + analgesic combination |
| Target | 5-HT1B/1D receptor (rizatriptan); COX inhibitor (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Rizatriptan is a triptan that acts as a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of dilated cranial blood vessels and reducing the release of inflammatory neuropeptides involved in migraine pathophysiology. Acetaminophen complements this mechanism by inhibiting prostaglandin synthesis, providing additive pain relief. The combination targets migraine through both vascular and analgesic pathways.
Approved indications
- Acute migraine with or without aura
Common side effects
- Dizziness
- Somnolence
- Asthenia/fatigue
- Chest pain/pressure
- Paresthesia
- Nausea
Key clinical trials
- A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: